Manufacturer record
Medinok Healthcare Pvt. Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
8 batches manufactured by Medinok Healthcare Pvt. Ltd (Puducherry) were declared Not of Standard Quality between March 2022 and April 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
8 records linked to Medinok Healthcare Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
0Banned or prohibited
0Recalled or suspended
8Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
8
NSQ batches since 2022
8
Products affected
Misbranded
Most common failure
Apr 2025
Latest alert
Flagged batches per year
2022 · 12025 · 7
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Glimepiride Tablets (Glimilive ? 4) | MDP-649Mfg 2024-09 · Exp 2026-08 | Misbranded (1) For the received sample Glimepiride Tablets (Glimilive ? 4) , The label is mentioned as ?Approved colour used? but common name of the permitted colour used in the formulation as prescribed under rule 127(2) of the Drugs Rules ,1945 was not mentioned. (2) The sample received is labelled as Glimepiride Tablets (Glimilive ? 4) , however Glimepiride Tablets is an official IP monograph (2022) hence should be labelled as Glimepiride Tablets IPMisbranded | State Lab PuducherryState lab | Apr 2025 |
| Aceclofenac With Paracetamol Tablets (S-DOL-P) | MDP-018Mfg 2024-04 · Exp 2026-03 | Misbranded The label of the container in the drug is mentioned as "Approved colour used" but the common name of the permitted colour used in the formulation as prescribed under rule 127 (2) of the drug rule was not mentioned.Misbranded | State Lab PuducherryState lab | Apr 2025 |
| PREGABALIN AND METHYLCOBALA MIN CAPSULES (Amalin Plus ) | MDP- 774Mfg ? · Exp ? | The sample received is labelled as PREGABALIN AND METHYLCOBALAMIN CAPSULES, however PREGABALIN AND METHYLCOBALAMIN CAPSULES is an official IP monograph (2022) hence should be labelled as PREGABALIN AND METHYLCOBALAMIN CAPSULES IP- MisbrandedMisbranded | PuducherryState lab | Feb 2025 |
| PANTOPROZOL E SODIUM (EC) & DOMPERIDONE (SR) CAPSULES (Tonixpro DSR) | MDP- 345Mfg ? · Exp ? | 1. The primary packaging label claims 'Each film coated tablet contains:' however, on physical observation the received sample is found to be 'Hard Gelatin Capsules'. 2.The received sample is labelled as 'PANTOPROZOLE SODIUM (EC) & DOMPERIDONE (SR) CAPSULES', however Pantoprazole Gastro- resistant and Domperidone Prolonged-release Capsules is an official IP monograph (2022) hence should be labelled as PANTOPRAZOLE SODIUM (EC) & DOMPERIDONE (SR) CAPSULES IP. 3.The sample name and the label claim of the drug states 'PANTOPROZOLE' instead of 'PANTOPRAZOLE' but the proper name of the drug should be written asprescribed under 96(1), (i)(A) of the Drugs & Cosmetics Act.- MisbrandedMisbranded | PuducherryState lab | Feb 2025 |
| CEFIXIME & LACTIC ACID BACILLUS TABLETS (AFIX- L 200) | MDP - 785Mfg ? · Exp ? | For the received sample Cefixime & Lactic Acid Bacillus tablets (AFIX- L 200), (i) The label on the secondary packaging, name of the colour information is concealed ,whereas the primary packaging label specifies 'Red oxide of Iron' as the colour. This discrepancy indicates a mismatch between the primary and secondary packaging labels. (ii) The primary packaging label claims the tablet colour is ' Red oxide of Iron' but physical verification of the tablet observed as pale yellow colour. - NSQLabelling | PuducherryState lab | Feb 2025 |
| Clopidogrel Tablet I.P 75 mg (Maxgrel - 75) | MDP - 309Mfg 2024-06 · Exp 2026-05 | (i) On the received sample, Presence of Spot and discoloration defects were observed which should not be present as per DCC Guidelines on Not Of Standard Quality (NSQ) Drugs Approved in 1993 (Annexure A) Tablets vide serial No.(i) Presence of Spot/discoloration. (ii)The label of the container in the drug is mentioned as 'Approved colour used' but the common name of the permitted colour used in the formulation as prescribed under rule 127 (2) of the drug rule was not mentioned. (iii) On the received sample, The name of the manufacturer and as prescribed under 96 (1) (iv) of the Drugs and Cosmetics Act. (iv) On the received sample,the label details of the primary packing does not match with that of the secondary packing (Excipients ?q.s is not mentioned in primary packing)- NSQ the address of the premises of the manufacturer appears in an inconspicuous manner on the label whereas they should appear in a conspicuous mannerLabelling | State Lab PuducherryState lab | Jan 2025 |
| Calcium Carbonate & Vitamin D3 Tablets (VICTOCAL ? D3) | MDP - 746Mfg 2024-09 · Exp 2026-08 | The sample received is labelled as CALCIUM CARBONATE & VITAMIN D3 TABLETS, however CALCIUM CARBONATE & VITAMIN D3 TABLETS is an official IP monograph (2022) hence should be labelled as CALCIUM AND VITAMIN D3 TABLETS IP. - Label issueLabelling | State Lab PuducherryState lab | Jan 2025 |
| BENUGOLD (Methylcobalamin, Alpha Lipoic Acid, Pyridoxine, Benfotiamine, Biotin & Chromium Polynicotinate Capsule) | MHD-1611Mfg 2021-01 · Exp 2022-12 | Assay of Alpha Lipoic AcidAssay | CDL KolkataCDSCO lab | Mar 2022 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.